Memory Pharmaceuticals Nominates New Drug Candidate MEM 63908

Memory Pharmaceuticals has announced the nomination of MEM 63908, a new drug candidate for the treatment of Alzheimer's disease.

MEM 63908 is the fifth development candidate in Memory Pharmaceuticals' pipeline. MEM 63908 is a partial agonist of the nicotinic alpha-7 receptor and belongs to a family of novel nicotinic alpha-7 receptor agonists that the company is currently developing under its 2003 collaboration with Roche. Found primarily in the brain, nicotinic alpha-7 receptors have a number of properties that suggest they may play a unique role in neuronal function.